Cargando…

Neoepitope targets of tumour-infiltrating lymphocytes from patients with pancreatic cancer

BACKGROUND: Pancreatic cancer exhibits a poor prognosis and often presents with metastasis at diagnosis. Immunotherapeutic approaches targeting private cancer mutations (neoantigens) are a clinically viable option to improve clinical outcomes. METHODS: 3/40 TIL lines (PanTT26, PanTT39, PanTT77) were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meng, Qingda, Valentini, Davide, Rao, Martin, Moro, Carlos Fernández, Paraschoudi, Georgia, Jäger, Elke, Dodoo, Ernest, Rangelova, Elena, del Chiaro, Marco, Maeurer, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325142/ https://www.ncbi.nlm.nih.gov/pubmed/30377343 http://dx.doi.org/10.1038/s41416-018-0262-z

Ejemplares similares

Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma
por: Valentini, Davide, et al.
Publicado: (2018)

Correction: Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma
por: Valentini, Davide, et al.
Publicado: (2018)

CMV and EBV targets recognized by tumor-infiltrating B lymphocytes in pancreatic cancer and brain tumors
por: Meng, Qingda, et al.
Publicado: (2018)

Generation of tumor-infiltrating lymphocytes from pancreatic cancer lesions for cellular therapy
por: Meng, Qingda, et al.
Publicado: (2014)

Prediction of improved survival in patients with pancreatic cancer via IL-21 enhanced detection of mesothelin epitope-reactive T-cell responses
por: Meng, Qingda, et al.
Publicado: (2018)

KRAS RENAISSANCE(S) in Tumor Infiltrating B Cells in Pancreatic Cancer
por: Meng, Qingda, et al.
Publicado: (2018)

Enhanced tumor-infiltrating lymphocytes (eTIL) for cellular therapy of patients with pancreatic cancer or glioblastoma
por: Meng, Qingda, et al.
Publicado: (2015)

Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery
por: de Sousa, Eric, et al.
Publicado: (2021)

A fast assay to gauge for TAA-reactive T cells in PBMCS from patients with pancreatic cancer
por: Rangelova, Elena B, et al.
Publicado: (2014)

Clinically Relevant Immune Responses against Cytomegalovirus: Implications for Precision Medicine
por: Lérias, Joana R., et al.
Publicado: (2019)

T-Cell Therapy: Options for Infectious Diseases
por: Parida, Shreemanta K., et al.
Publicado: (2015)

Rapid expansion of TILs from patients with glioma and recognition of autologous tumor
por: Zhenjiang, Liu, et al.
Publicado: (2014)

Cytokine Networks and Survivin Peptide-Specific Cellular Immune Responses Predict Improved Survival in Patients With Glioblastoma Multiforme
por: Zhenjiang, Liu, et al.
Publicado: (2018)

Epstein–Barr virus- and cytomegalovirus-specific immune response in patients with brain cancer
por: Liu, Zhenjiang, et al.
Publicado: (2018)

Expression of TAAs in glioblastoma and expansion of anti-TAA -reactive T cells
por: Dodoo, Ernest, et al.
Publicado: (2014)

B in TB: B Cells as Mediators of Clinically Relevant Immune Responses in Tuberculosis
por: Rao, Martin, et al.
Publicado: (2015)

IL-2, IL-15 and IL-21 expand T cells for targeted adoptive therapy
por: Liu, Zhenjiang, et al.
Publicado: (2015)

Mesothelin-specific Immune Responses Predict Survival of Patients With Brain Metastasis
por: Zhenjiang, Liu, et al.
Publicado: (2017)

Immunometabolism and Pulmonary Infections: Implications for Protective Immune Responses and Host-Directed Therapies
por: Rao, Martin, et al.
Publicado: (2019)

Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis
por: Zumla, Alimuddin, et al.
Publicado: (2016)

Microbes as Master Immunomodulators: Immunopathology, Cancer and Personalized Immunotherapies
por: Lérias, Joana R., et al.
Publicado: (2020)

NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma
por: Liu, Zhenjiang, et al.
Publicado: (2017)

Trained Immunity for Personalized Cancer Immunotherapy: Current Knowledge and Future Opportunities
por: Lérias, Joana R., et al.
Publicado: (2020)

Mesothelin as a novel biomarker and immunotherapeutic target in human glioblastoma
por: Liu, Zhenjiang, et al.
Publicado: (2017)

Human Pancreatic Carcinoma-Associated Fibroblasts Promote Expression of Co-inhibitory Markers on CD4(+) and CD8(+) T-Cells
por: Gorchs, Laia, et al.
Publicado: (2019)

The neoepitope landscape in pediatric cancers
por: Chang, Ti-Cheng, et al.
Publicado: (2017)

Pan-cancer analysis of neoepitopes
por: Teku, Gabriel N., et al.
Publicado: (2018)

The concept of rapid rescue radiosurgery in the acute management of critically located brain metastases: A retrospective short-term outcome analysis
por: Sinclair, Georges, et al.
Publicado: (2018)

Adaptive hypofractionated gamma knife radiosurgery in the acute management of brainstem metastases
por: Sinclair, Georges, et al.
Publicado: (2019)

Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma
por: D’Angelo, Alberto, et al.
Publicado: (2019)

Delayed Gastric Emptying after Pancreatic Surgery: Analysis of Factors Determinant for the Short-term Outcome
por: Noorani, A., et al.
Publicado: (2016)

Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display
por: Wickström, Stina L., et al.
Publicado: (2019)

Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours
por: Iacovazzo, Donato, et al.
Publicado: (2019)

Intron retention is a source of neoepitopes in cancer
por: Smart, Alicia C., et al.
Publicado: (2018)

The neoepitope landscape of breast cancer: implications for immunotherapy
por: Narang, Pooja, et al.
Publicado: (2019)

Combination therapies utilizing neoepitope-targeted vaccines
por: Lee, Karin L., et al.
Publicado: (2020)

Boosting Antitumor Immunity with an Expanded Neoepitope Landscape
por: Nagel, Remco, et al.
Publicado: (2022)

S47. Tumour infiltrating lymphocytes - a predictive marker?
por: Galon, J
Publicado: (2014)

Tumour-infiltrating lymphocytes: from prognosis to treatment selection
por: Brummel, Koen, et al.
Publicado: (2022)

Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma
por: Naghavian, Reza, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hsn78tebge8cnmcnj7eq75nvmm